Barclays analyst Steve Valiquette raised the firm’s price target on Tenet Healthcare to $70 from $67 and keeps an Overweight rating on the shares. The company’s Q4 results present broad improvement in volume growth and cost control, the analyst tells investors in a research note. In addition, its 2023 outlook bracketed consensus broadly and implied return to normalized growth, says the firm.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on THC:
- Tenet Healthcare price target raised to $65 from $48 at Deutsche Bank
- Tenet Healthcare price target raised to $66 from $60 at Truist
- Tenet Healthcare price target raised to $60 from $57 at Stephens
- Tenet Healthcare sees 2023 adjusted EPS $4.68-$5.85 vs. $7.58 in 2022
- Tenet Healthcare reports Q4 adjusted EPS $1.96 vs. $2.70 a year ago
